Opioid Dependence — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for opioid dependence. 175 active patents protecting 2 drugs from 2+ originators. First major cliff: 2027. Daily refresh.

2
Approved drugs
175
Active US patents
67/100
Avg vulnerability
$1.6B
Annual revenue covered

Originators in Opioid Dependence

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Indivior 96 patents Purdue Pharma Lp 79 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating opioid dependence. Each bar = one year. Y-axis scaled to peak year (93 patents).

7
26
33
27
8
29
10
30
16
31
93
32
7
35
1
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Subutex
Buprenorphine Hydrochloride
 Indivior 96 62 $800M 2027-07-23
Subutex
BUPRENORPHINE
 Purdue Pharma Lp 79 71 $800M 2026-07-31

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236292 Subutex method of use 88 2027-01-10
8236292 Subutex method of use 88 2027-01-10
8236292 Subutex method of use 88 2027-01-10

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9522188 Subutex formulation 42 2035-04-24
9522188 Subutex formulation 42 2035-04-24
9522188 Subutex formulation 42 2035-04-24
10946010 Subutex formulation 42 2032-09-18
8940330 Subutex formulation 42 2032-09-18
9259421 Subutex formulation 42 2032-09-18
8940330 Subutex formulation 42 2032-09-18
9439900 Subutex formulation 42 2032-09-18
9259421 Subutex formulation 42 2032-09-18
9439900 Subutex formulation 42 2032-09-18

Related